Published Guidance, NICE advice and quality standards

Skip to filtersSkip to results

Skip to results

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme 2 selected

Guidance programme

Showing 776 to 794 of 794

TitleReference numberPublishedLast updated
Venetoclax for treating chronic lymphocytic leukaemiaTA796
Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitableTA765
Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitableTA787
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemiaTA663
Venetoclax with rituximab for previously treated chronic lymphocytic leukaemiaTA561
Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal)TA731
Vernakalant for the rapid conversion of recent onset atrial fibrillation to sinus rhythm (terminated appraisal)TA675
Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tractTA272
Vismodegib for treating basal cell carcinomaTA489
Voclosporin with mycophenolate mofetil for treating lupus nephritisTA882
Volanesorsen for treating familial chylomicronaemia syndromeHST13
Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutationsHST11
Vortioxetine for treating major depressive episodesTA367
Voxelotor for treating haemolytic anaemia caused by sickle cell diseaseTA981
Vutrisiran for treating hereditary transthyretin-related amyloidosisTA868
Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoeaTA605
Zanubrutinib for treating chronic lymphocytic leukaemiaTA931
Zanubrutinib for treating Waldenstrom's macroglobulinaemiaTA833
Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments (terminated appraisal)TA978

Results per page

  1. 10
  2. 25
  3. 50
  4. All